Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Non-Small Cell Lung Cancer
Epigenomics AG Demonstrates Feasibility of Convenient Blood Test for Lung Cancer Detection in Clinical Study
July 22nd, 2007
Epigenomics AG (Frankfurt, Prime Standard: ECX) takes a further step towards launching a convenient blood-based lung cancer screening test that could considerably improve the early detection of lung cancer, the most common cause of cancer-related death. The molecular diagnostics company today announced positive data resulting from a clinical study as part of its lung cancer screening test development program. The program aims at developing a blood based test for the reliable and convenient early detection of lung cancer. In an initial study last year Epigenomics identified numerous candidate DNA methylation biomarkers that appear in lung tumors, but not in normal lung...
Source: Medical Devices & Surgical Technology Week (2007-07-22)
|
